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Comments on: “In vitro efficacy of hyperbaric oxygen therapy
against Leishmania tropica promastigotes and amastigotes”
Yalçın ÖNEM1, Vedat TURHAN2

We read with great interest the paper by Koru et al. (1), in which in vitro efficacy of hyperbaric
oxygen (HBO) therapy against Leishmania tropica promastigotes and amastigotes was investigated.
We applaud their efforts to seek new treatments for leishmaniasis, which is an important health
problem in Turkey. However, we have some concerns regarding the clinical usability of HBO
therapy in the treatment of leishmaniasis.
Due to its antiinfective properties, HBO therapy is frequently used in the treatment of certain
infectious diseases (gas gangrene, necrotizing fasciitis, diabetic foot infections, etc.) and its
effectiveness has also been investigated in several other indications such as fungal and parasitic
infections (2). In their study, Koru et al. exposed L. tropica promastigotes and amastigotes in
culture dishes to 3 different HBO therapy protocols of 2 h, 4 h, and 6 h. The dose of HBO therapy is
determined by 2 measures, the duration and the pressure of the treatment. Due to pulmonary and
neurologic toxicity of HBO therapy, the highest operating pressure is 2.8 ATA and the duration of
oxygen breathing periods does not exceed 2 h. From this perspective, only the 2-h HBO protocol
in the study of Koru et al. was clinically relevant and the 4-h and 6-h HBO protocols are not
applicable to humans due to the risk of oxygen toxicity. When we look at the data from the 2-h
HBO experiments, we see that HBO therapy for 2 h did not affect motility and viability of L. tropica
promastigotes (Figure 1 in the paper of Koru et al.). Moreover, in contrast to 4-h and 6-h HBO
protocols, HBO therapy for 2 h did not show significant cytotoxicity on L. tropica promastigotes
(Figure 3 in the paper of Koru et al.) and L. tropica amastigotes (Figure 5 in the paper of Koru et al.).
Additionally, despite the fact that HBO therapy for 2 h reduced growth of L. tropica promastigotes,
it did not reach statistical significance, as shown in Figure 4 in the paper of Koru et al.
On the other hand, the partial pressure of oxygen in human tissues during HBO therapy will
never reach the same level of that in the culture dishes. As Koru et al. have shown, the beneficial
effects of HBO therapy are related to reactive oxygen species and free radicals, and the amount
of oxidative products produced by HBO therapy is directly proportional to the partial pressure of
oxygen. Therefore, the efficacy of HBO therapy against L. tropica promastigotes and amastigotes
will be lower in human tissues compared to that in culture dishes.
We think that the efficacy of HBO therapy at 2.5 ATA for 2 h against L. tropica promastigotes
and amastigotes is limited. However, combination of HBO therapy with antimicrobial drugs may
be an alternative approach (3). As recommend by Koru et al., we think that future studies should
investigate the efficacy of the combination of HBO therapy and antiparasitic drugs, which reduce
the levels of antioxidant enzymes in parasites.
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We would like to thank to Önem and Turhan for
their comments. In our in vitro study, we assessed
the effective dose and duration of hyperbaric
oxygen (HBO) application that could be tolerated
by humans on Leishmania tropica promastigote
and amastigote forms and detected the cytotoxic
effect of HBO, which began 2 h after treatment and
reached a maximum level after 6 h in treated groups.
Promastigotes that are in the infective stage, injected
by sandflies, transform in macrophages and other
types of mononuclear phagocytic cells into the tissue
stage of the parasite (1). Therefore, only amastigote
forms are found in human tissues and HBO’s effect
on promastigote forms has to be examined in vitro.
Thus, “the efficacy of HBO therapy against L. tropica
promastigotes and amastigotes will be lower in
human tissues compared to that in culture dishes”
is not an accurate phrase in the letter of Önem and
Turhan. Most HBO treatments, including those for
wound healing, last about 2 h. Treatments for acute
indications, such as carbon monoxide poisoning, gas
gangrene, and ischemic and traumatic crush injuries,

may last as long as 4 h, and under rare circumstances,
some diving injuries may require treatment even
longer than 8 h (2). Pulmonary oxygen toxicity is a
very rare complication that can occur with cumulative
effects in long-lasting sessions (60–80 sessions) and
can improve rapidly when the exposure is terminated
(3). Therefore, the comments of Önem and Turhan
about HBO treatment protocol are inaccurate.
The obligate intracellular parasite Leishmania has
developed numerous highly successful strategies for
preventing activation of effective antimicrobial agents
such as nitric oxide, oxygen radical generation, and
cytokine production. HBO increases generation of
reactive oxygen species and free radicals and inhibits
the antioxidant defense mechanisms of Leishmania
spp. (4). We believe that HBO can be effective for
treatment of leishmaniasis with enhanced effects of
antileishmanial drugs. Further in vivo and in vitro
studies are needed for its more reliable use along
with chemotherapy in the treatment of patients, as
emphasized by Önem and Turhan.
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